AbbVie and Boehringer Ingelheim to collaborate on development of BI 655066 for psoriasis and on early stage BI 655064
AbbVie and Boehringer Ingelheim announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal antibody in Phase III development for psoriasis. They also are evaluating the potential of this biologic therapy in Crohn's disease, psoriatic arthritis and asthma.
In addition to the anti-IL-23 antibody, AbbVie gains rights to an anti-CD-40 antibody, BI 655064, currently in Phase I development. Boehringer Ingelheim will retain responsibility for further development of BI 655064, and AbbVie may elect to advance the programme after completion of certain undisclosed clinical achievements.
Comment: In recent Phase II studies BI 655064 has shown itself superior to Stelara (ustekinumab).
910 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.